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DOI 10.1016/j.ccr.2012.02.029SUMMARYConstitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic
leukemia (T-ALL). Although four distinct class I PI3K isoforms (a, b, g, d) could participate in T-ALL pathogen-
esis, none has been implicated in this process. We report that in the absence of PTEN phosphatase tumor
suppressor function, PI3Kg or PI3Kd alone can support leukemogenesis, whereas inactivation of both
isoforms suppressed tumor formation. The reliance of PTEN null T-ALL on the combined activities of
PI3Kg/d was further demonstrated by the ability of a dual inhibitor to reduce disease burden and prolong
survival in mice as well as prevent proliferation and promote activation of proapoptotic pathways in human
tumors. These results support combined inhibition of PI3Kg/d as therapy for T-ALL.INTRODUCTION
Constitutive activation of the phosphoinositide 3-kinase (PI3K)/
Akt signal transduction pathway is a common event in cancer,
promoting the growth, proliferation, and survival of various types
of tumors including T cell acute lymphoblastic leukemia (T-ALL)
(Yuan and Cantley, 2008; Zhao and Vogt, 2008; Gutierrez et al.,
2009; Palomero et al., 2008; Silva et al., 2008; Larson Gedman
et al., 2009). Class I PI3Ks are a family of lipid kinases that
generate the potent second messenger phosphatidylinositol-
3,4,5 trisphosphate (PIP3) in response to ligation of a number
of distinct cell surface receptors (Katso et al., 2001; Cantley,
2002). This results in the activation of Akt as well as numerousSignificance
Loss of PTEN function is a frequent occurrence in cancer result
pathogenesis. Consequently, much emphasis has been placed
report that PI3Kg and PI3Kd act as a tumorigenic bottleneck in
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between PTEN and particular PI3K isoforms in regulating bo
sustaining tumor cell proliferation and survival.downstream effector molecules, which ultimately promote cell
growth and survival. Class I PI3Ks are heterodimeric molecules
composed of a regulatory and a catalytic subunit, the latter
consisting of four unique isoforms that include p110a, p110b,
p110g, and p110d. Each is capable of regulating distinct
biological functions in normal tissues and cellular compart-
ments. However, some overlap in activity does exist, as is the
case for thymocytes where the combined activities of PI3Kg
and PI3Kd contribute to cellular processes required for the
generation and function of mature T cells (Webb et al., 2005;
Swat et al., 2006; Ji et al., 2007). Although the importance of
these two PI3K isoforms in T cell biology is well established
(Okkenhaug and Vanhaesebroeck, 2003), what role, if any, theying in unbridled PI3K/Akt signaling that contributes to tumor
on developing inhibitors that target this pathway. Here, we
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nt in our understanding of the dynamic interplay that exists
th normal and abnormal T cell development as well as in
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Role of PI3Kg and PI3Kd in PTEN Null T-ALLplay in malignant transformation and tumor cell survival remains
to be determined.
Previously, it has been reported that p110a is involved in onco-
genesis because function-enhancing mutations in this catalytic
subunit are found in many cancers of solid organs (Samuels
et al., 2004; Zunder et al., 2008). In contrast, cancer-specific
mutations have yet to be identified for the other p110 isoforms.
That said, overexpression of p110b, p110g, or p110d in an
in vitro culture system induces cellular transformation (Kang
et al., 2006). Moreover, increased or preferential expression of
p110g and p110d has been described in chronic and acute
forms of myeloid leukemia, respectively (Hickey and Cotter,
2006; Sujobert et al., 2005). However, to our knowledge, overex-
pression of specific PI3K isoforms has not been reported for
T-ALL, and mutations in PI3Ka are rare, suggesting that they
are not a major contributor to its pathogenesis (Gutierrez et al.,
2009; Lo et al., 2009).
PTEN is a nonredundant plasma-membrane phosphatase that
is responsible for counteracting the potential cancer-promoting
activities of class I PI3K (Sulis and Parsons, 2003; Salmena
et al., 2008). It does so by limiting the levels of PIP3 generated
in response to the activation of these lipid kinases. Clinically,
mutations in the PTEN tumor suppressor gene are common in
multiple types of human cancer, resulting in unbridled PI3K/Akt
signaling as well as conferring resistance to chemotherapeutic
agents (Carnero et al., 2008; Huang and Hung, 2009). It has
been well established that deletion of the tumor suppressor
gene PTEN in T cell progenitors drives themalignant transforma-
tion of these cells within the thymus of mice (Suzuki et al., 2001;
Hagenbeek and Spits, 2008; Liu et al., 2010). Moreover, the
resulting tumors possess similar genetic and biochemical aber-
rations associated with a subset of patients with T-ALL including
hyperactivation of the PI3K/Akt signaling pathway (Maser et al.,
2007; Guo et al., 2008). In fact Gutierrez et al. (2009) have
reported a loss of PTEN function due to mutations or deletions
in approximately 40% of primary T-ALL samples, suggesting
that hyperactivation of the PI3K/Akt signaling pathway is
a common feature of this hematological malignancy. Based on
these clinical observations and known reliance of thymocyte
development on PI3Kg and PI3Kd, we set out to determine
whether these nonclassical oncogenes contribute to leukemo-
genesis and if it is possible to exploit tumor cell ‘‘addiction’’ to
the activity of distinct PI3K isoforms, thus permitting the rational
design of a chemotherapeutic agent to treat T-ALL.
RESULTS
PI3Kg or PI3Kd Can Support Malignant Transformation
of T Cells
We crossed mice containing both Pten alleles floxed by the loxP
Cre excision sites with Lck-cre transgenic animals (Lck/Ptenfl/fl)
alone or together with those lacking p110g, encoded by Pik3cg,
and/or p110d, encoded byPik3cd, catalytic subunits. Consistent
with previous studies, >85% of Lck/Ptenfl/fl mice develop T-ALL
and eventually succumb to the disease (median survival of
140 days), which was confirmed by flow cytometric analysis
(Figures 1A and 1B). In contrast to PTEN null tumors of solid
organs that have been reported to rely on PI3Kb activity (Jia
et al., 2008; Wee et al., 2008), tumorigenesis in the context of460 Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc.a deficiency of PTEN in T cell progenitors appears to be critically
dependent on PI3Kg and PI3Kd. This is evidenced by themarked
delay in the onset of disease and increased survival of Lck/
Ptenfl/fl;Pik3cg/;Pik3cd/ triple-mutant mice (TKO) because
<20% of animals succumb to T-ALL by 220 days. However,
the activity of either isoform alone was sufficient to promote
tumor formation, yielding similar median survival times for
Lck/Ptenfl/fl;Pik3cg/ and Lck/Ptenfl/fl;Pik3cd/ mice (175
versus 178 days, respectively). Comparable percentages of
these animals developed and died of T-ALL (65% versus 64%,
respectively), and tumors had evidence of activation of the
PI3K/Akt signaling pathway, albeit much reduced as compared
to those from Lck/Ptenfl/fl animals (Figure 1C). However, there
was no evidence of overexpression of any Pik3c isoform in
thymic tumors (Figure 1D).
Further evidence demonstrating that it is the unleashed activ-
ities of PI3Kg and PI3Kd that provide the signals necessary for
the development of T-ALL is suggested by the continued reduc-
tion in thymus size and cellularity in 6-week-old TKO mice (Fig-
ure 2A). Although absence of PTEN should permit unrestricted
activity of all four class I PI3K isoforms, it appears that PI3Ka
and PI3Kb cannot adequately compensate for their g and
d counterparts as evidenced by the persistent diminution in the
total number of CD4+CD8+ double-positive thymocyte popula-
tion and near-basal levels of phosphorylated Akt (Ser473) as
compared to mice deficient in PTEN alone (Figures 2A and 2B).
Cellular alterations associated with p110g/d double deficiency
also persisted in the peripheral blood and in secondary lymphoid
organs of TKO mice and included a paucity of CD3+ T cells
(Figures 2C and 2D). No active tumor was found in peripheral
blood or spleen of the surviving animals at 7 months of age
as determine by absence of staining for the proliferation marker
Ki67 on Thy1.2-positive cells (Figure 2E).Effect of PI3Kg/PI3Kd Dual Inhibition on Thymocyte
Signaling and Development
In order to ascertain whether PI3Kg and PI3Kd are also required
for tumor maintenance and can be targeted therapeutically in
T-ALL, we generated a small molecule that preferentially inhibits
the function of both p110g and p110d catalytic domains, desig-
nated CAL-130 (Figure 3A). IC50 values of this compound were
1.3 and 6.1 nM for p110d and p110g, respectively, as compared
to 115 and 56 nM for p110a and p110b. Importantly, this small
molecule does not inhibit additional intracellular signaling
pathways (i.e., p38 mitogen-activated protein kinase or insulin
receptor tyrosine kinase) that are critical for general cell function
and survival (Table 1; see Table S1 available online). To demon-
strate that CAL-130 can block the activities of both PI3Kd and
PI3Kg in thymocytes, we evaluated its ability to prevent phos-
phorylation of Akt (Ser473) and calcium flux in response to
T cell receptor (TCR) crosslinking. Previously, we have shown
that the combined activities of these two class I PI3K isoforms
are necessary for phosphorylation of this protein kinase in this
cell population (Swat et al., 2006). Consistent with these results,
CAL-130 treatment of thymocytes harvested from 6-week-old
WT animals prevented TCR-induced Akt phosphorylation
and attenuated calcium flux to levels observed for their
Pik3cg/;Pik3cd/ counterparts (Figures 3B, 3C, and S1A).
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Figure 1. PI3Kg or PI3Kd Can Support Leukemogenesis in the Context of PTEN Deficiency
(A) Kaplan-Meyer survival curves demonstrating the requirement for PI3Kg and PI3Kd activity in the development of PTEN null T-ALL. All animals were followed
for a period of 7 months.
(B) Representative flow cytometric profiles of peripheral blood from diseased mice lacking p110g or p110d in the absence of PTEN in T cell progenitors. Forward
scatter (FSC) and Ki67 staining are indicators of cell size and proliferation, respectively. Thy 1.2 expression identifies T-lineage cells.
(C) Representative immunoblots depicting p110g, p110d, and PTEN expression as well as Akt activation state (phosphorylation of Ser473) in thymic lysates from
the same animals.
(D) Quantitative reverse-transcription PCR analysis of Pik3c (a/b/g/d) transcript levels in WT thymocytes (n = 5) and tumors (n = 5) harvested from Lck/Ptenfl/fl
mice. Error bars represent ±SD. The difference inPik2c expression levels between theWT thymocytes and tumor cells was statistically significant (*p < 0.05) using
a Student’s t test.
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Role of PI3Kg and PI3Kd in PTEN Null T-ALLTo assess the in vivo efficacy of the inhibitor, we determined its
effects on thymi of 6-week-oldWTmice, specifically for its ability
to recapitulate the phenotype observed when both p110g and
p110d are deficient. Animals received 10 mg kg1 of the inhibitor
orally, which was sufficient to maintain plasma concentrations of
0.33 ± 0.18 mM at the end of 8 hr (Figure 3D). Notably, this dose
did not affect either plasma glucose or insulin levels in contrast
to the metabolic perturbations associated with tissue-specific
deficiencies in p110a and p110b (Figures 3E and 3F) (Jia et al.,
2008; Sopasakis et al., 2010). CAL-130 was also found to have
a limited ability to impair PDGF-induced activation of PI3Ka as
compared to the pan-PI3K/mTOR inhibitor BEZ235 (Figure S1B).
Similarly, platelets harvested from Pik3cg/;Pik3cd/ mice
2 hr post-administration of CAL-130 had no obvious defect in
ADP-mediated platelet aggregation, a process known to rely
predominantly on PI3Kb (Figure S1C) (Jackson et al., 2005).
However, CAL-130 treatment (10mg kg1 every 8 hr) for a period
of 7 days markedly affected the size, cellularity, and overall
architecture of the thymus faithfully reproducing the phenotype
associated with Pik3cg/;Pik3cd/mice (Figure 3G). In partic-ular there was a 18-fold reduction in total thymocyte number in
comparison to controls, which was primarily due to the loss of
DP population (Figure 3H). These observations are consistent
with the ability of CAL-130 to preferentially block the function
of both PI3Kg and PI3Kd.
Antileukemic Effects of Pharmacological Inhibition of
PI3Kg and PI3Kd in PTEN Null T-ALL Tumors in Mice
The clinical significance of interfering with the combined activi-
ties of PI3Kg and PI3Kd was determined by administering
CAL-130 to Lck/Ptenfl/fl mice with established T-ALL. Candidate
animals for survival studies were ill appearing, had a white blood
cell (WBC) count above 45,000 ml1, evidence of blasts on
peripheral smear, and a majority of circulation cells (>75%)
staining double positive for Thy1.2 and Ki-67. Mice received an
oral dose (10 mg kg1) of the inhibitor every 8 hr for a period of
7 days and were then followed until moribund. Despite the
limited duration of therapy, CAL-130 was highly effective in
extending the median survival for treated animals to 45 days
as compared 7.5 days for the control group (Figure 4A).Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc. 461
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Figure 2. Persistence of Cellular and Structural Defects in Thymi Associated with a Combined Deletion of p110g/p110d and PTEN
(A) Hematoxylin and eosin staining (H&E) and flow cytometric analyses of thymi derived from 6-week-old mice lacking both p110g and p110d catalytic subunits in
the presence or absence of PTEN. The panels are representative of data from five animals in each group.
(B) Immunoblots assessing for Akt phosphorylation (Ser473) and PTEN levels in thymocyte lysates.
(C) Number of WBC and T cell subsets in the peripheral blood of the same animals. *ns (not significant) for Pik3cg/;Pik3cd/ versus TKO; **p < 0.01 for WT
versus TKO.
(D and E) Representative (D) micrografts of H&E peripheral lymph nodes and spleen and (E) flow cytometry plots of blood and spleen from triple mutant animals
(n = 5 mice per genotype). Histological identification of T cells was by immunoperoxidase detection of CD3. Scale bars correspond to 200 mm in secondary
lymphoid organs and to 500 mm in thymi. Data represent the mean ± SD.
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Role of PI3Kg and PI3Kd in PTEN Null T-ALLTo determine the effect of CAL-130 on disease burden, we
performed sequential blood counts and peripheral smears as
well as flow cytometric analyses on Lck/Ptenfl/fl mice pre- and
post-administration of the inhibitor (Figures 4B and S2A–S2C).
All animals showed a dramatic reduction in WBC count by day
4 reflected in the loss of the highly proliferative blast population
(Thy1.2/Ki-67 double positive, high FSC-H), which remained at
low levels for the duration of treatment. Moreover, both CD4
single-positive and CD4/CD8 double-positive T-ALL responded
to CAL-130, which corresponded with an increase in apoptosis
detected as sub-G0 population after propidium iodide (PI) stain-
ing on days 4–7. Treatment of diseased Lck/Ptenfl/fl;Pik3cg/
mice but not their Lck/Ptenfl/fl counterparts with the PI3Kd selec-
tive inhibitor IC87114 (10 mg kg1 every 8 hr) produced similar
results, confirming the critical reliance of PTEN null tumors on
the combined activities of PI3KgandPI3Kd (Figures 4CandS2D).462 Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc.Further evidence to support the ability of CAL-130 to reduce
tumor burden was obtained by bioluminescent imaging. Ptenfl/fl
mice were crossed with a strain in which a luciferase cDNA,
preceded by a LoxP-stop-LoxP cassette, was introduced into
the ubiquitously expressed ROSA26 locus (Safran et al., 2003).
Progenies were then crossed with Lck-cre transgenics to delete
Pten in T cell progenitors and induce expression of luciferase
(Lck/Ptenfl/fl;Gt(ROSA)26Sortm1(Luc)Kael/J). Imaging of T-ALL
tumor-bearing animals was performed just prior to and after
4 days of treatment with CAL-130. Signals at day 4 were dramat-
ically lower in treated animals, consistent with the reduction in
the WBC count and the CD4 single-positive population of tumor
cells (Figure 4D). Moreover, weights of thymi, liver, spleen,
and kidneys from treated Ptenfl/fl mice were significantly less
than that for animals that received vehicle control for 7 days
(Figure 4E).
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Figure 3. Inhibitory Profile of CAL-130
(A) Chemical structure of CAL-130.
(B and C) Effect of the inhibitor on (B) Akt phosphorylation (Ser473) or (C) Ca2+ flux in purified thymocytes from WT or Pik3cg/;Pik3cd/ animals in response
to TCR crosslinking. Data are representative of three separate experiments.
(D) Plasma concentrations of CAL-130 in mice after a single oral dose (n = 4).
(E and F) Plasma glucose (E) and corresponding insulin levels (F) in WT mice before and after receiving a single dose of inhibitor (10 mg kg1). p > 0.5 for glucose
and p > 0.2 for insulin as compared to baseline (n = 15 mice per time point; ns, not significant).
(G) Phenotypic analyses of thymi from mice treated with either CAL-130 (10 mg kg1 every 8 hr) or vehicle control for 7 days. The panels are representative of
data from five animals in each group.
(H) Total DP thymocyte count in the same animals in (G). Results are compared to PI3Kg/d double-knockout mice. Data represent the mean ± SD.
See also Figure S1.
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Table 1. P110 Catalytic Domain Selectivity of CAL-130 as
Assessed by Ambit KinomeScan Screening
Ambit Gene
Symbol
Control
Binding (%)
Ambit Gene
Symbol
Control
Binding (%)
PIK3CA 12 PIK3CG 3.2
PIK3CB 10 PIK3CD 0.2
CAL-130 (10 mM) was evaluated for its ability to prevent tagged kinases
from interacting with immobilized ‘‘bait’’ ligand (Fabian et al., 2005;
Karaman et al., 2008). Results are reported as percentage (%) of control
binding, where lower numbers indicate stronger interactions with the
tagged kinase. Values >35% are considered ‘‘no hits.’’ PI3Kd had the
lowest percentage of control binding at 0.2% followed by PI3Kg at
3.2%, indicating a high probability of a potent interaction. A total of 353
kinases were assessed in the screen (Table S1).
Cancer Cell
Role of PI3Kg and PI3Kd in PTEN Null T-ALLReliance of PTEN Null Human T-ALL on PI3Kg and PI3Kd
To test whether CAL-130 may have similar effects on human
tumors, we first analyzed the response of T-ALL cell lines to
the compound. Incubation of cultured cells with CAL-130, but
not inhibitors of either PI3Kg or PI3Kd, prevented proliferation
and promoted apoptosis within 24 hr, which persisted over
4 days of treatment (Figures 5A, 5B, and S3A–S3J). To further
demonstrate that the combined activities of PI3Kg and PI3Kd
are essential for these processes, we utilized an shRNA vector
that targeted the p110g catalytic domain in CCRF-CEM cells.
Western blot analysis revealed a >95% reduction in expression
of p110g with no effect on the other isoforms (Figure 5C, inset).
Subsequent incubation of these cells with the PI3Kd-specific
inhibitor IC87114 prevented proliferation and promoted
apoptosis as observed for nontransfected CCRF-CEM exposed
to CAL-130 (Figures 5C and 5D). In contrast, IC87114 had no
major effect on cells containing empty vector alone; neither did
siRNA knockdown of either p110a or p110b (Figures S3K–
S3N). These observations are consistent with our in vivo studies
demonstrating that PI3Kg and PI3Kd are strictly required for the
proliferation and survival of T-ALL lymphoblasts. Moreover,
blockade of these two isoforms significantly enhanced the
apoptotic properties of dexamethasone, a drug of considerable
importance in the treatment of various lymphoid malignancies
including T-ALL (Figures 5E–5H) (Beesley et al., 2009).
It is well known that PI3K/Akt signaling pathway can play
a major role in cell-cycle progression and growth of tumors by
regulating the activation state of the downstream targets such
as glycogen synthase kinase-3b (GSK3b) and mTOR (Schmelzle
and Hall, 2000; Cohen and Frame, 2001). PI3K/Akt-mediated
phosphorylation suppresses the function of the former and
promotes the activity of the latter. Tumor cell survival, on the
other hand, is largely mediated by the ability of this pathway
to inactivate proapoptotic effectors such as the BH3-only proa-
poptotic protein BAD and to repress the expression of BIM, both
of which participate in the mitochondria-dependent cell death
pathway (Strasser et al., 2000; Duronio, 2008). Therefore, we
examined the ability of CAL-130 treatment to interfere with
such events. Indeed, CCRF-CEM cells exposed to increasing
concentration of drug exhibited a corresponding reduction and
complete abrogation of Akt (Ser473) phosphorylation at 2.5 mM
(Figure 6A). Downstream targets of this protein kinase were
also affected as evidenced by the reduction in phosphorylation464 Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc.of GSK3b and mTOR. Consistent with the importance of PI3K
in tumor cell survival, CAL-130 treatment resulted in a reduction
in phosphorylation of BAD, as well as an enhanced expression of
its counterpart BIM (including the L and S isoforms) (Figure 6B).
The latter would also explain in part the synergy between
CAL-130 and dexamethasone because BIM expression is
required for glucocorticoid-induced apoptosis (Erlacher et al.,
2005; Wang et al., 2003).
To assess the in vivo relevance of these observations, we
evaluated the ability of CAL-130 to prevent the proliferation of
CCRF-CEM cells implanted subcutaneously or to prolong the
survival of NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz that received these
cells intravenously. In the former, luciferase-expressing CCRF-
CEM cells were injected into the flanks of immunodeficient
mice and allowed to grow for 1 week before administering
vehicle control or inhibitor (10 mg kg1 every 8 hr) for a total of
4 days. In the latter, treatment commenced 3 days postinjection
of tumor cells for a total of 7 days. Bioimaging of subcutaneous
tumors revealed a 5-fold difference in luminescence in CAL-130-
treated versus vehicle control-treated animals (Figure 6C). This
translated into an increase in median survival time for treated
animals with systemic disease of 35 versus 23 days for mice
that received vehicle control alone (Figure 6D).
Because the continued passage of rapidly growing tumor
lines can result in genetic alterations distinct from the cell from
which it was originally derived, we also evaluated the effect of
CAL-130 on primary T-ALL samples isolated from patients with
active disease. Consistent with our animal studies, human tumor
cells devoid of PTEN were exquisitely sensitive to dual inhibition
of PI3Kg/d, but not single inhibition of PI3Kd, which resulted in
a reduction in tumor cell viability as well as in Akt phosphoryla-
tion in response to treatment (Figures 7A–7C; data not shown).
Interestingly, one primary sample that not only expressed
PTEN (T-ALL 4) but also high levels of phospho-Akt was as
responsive to CAL-130 as its PTEN null counterparts. This would
suggest that T-ALL sensitivity to a PI3Kg/d dual inhibitor might
correlate better with the degree of Akt phosphorylation rather
than with PTEN expression. As observed with primary mouse
T-ALL, human tumors did not appear to overexpress any of the
four class I PIK3C isoforms (Figure 7D).
DISCUSSION
Oncogenesis is a complex and multigenic process that often
involves constitutive activation of the PI3K signaling pathway.
Most notably are the gain-of-functionmutations frequently found
in PIK3CA, the gene that encodes for the p110a catalytic
subunit, and genetic alterations that lead to the inactivation of
the tumor suppressor gene PTEN (Samuels et al., 2004; Zunder
et al., 2008; Sulis and Parsons, 2003; Salmena et al., 2008). In the
latter scenario the possibility exists that the unregulated activity
of any of the four class I PI3K isoforms could drive tumor devel-
opment. For instance, previous reports demonstrate that PI3Kb
is essential for the induction, growth, and survival of PTEN-
deficient tumors of epithelial cell origin (Jia et al., 2008; Wee
et al., 2008). Moreover, it has been suggested that all class I
PI3K isoforms are capable of coupling to upstream signaling
pathways in which they are not normally engaged, thus com-
pensating for inhibition/genetic deletion of a particular isoform
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See also Figure S2.
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Figure 5. Contribution of PI3Kg and PI3Kd to the Growth and Survival of PTEN Null Human T-ALL Tumor Cell Lines
(A and B) Proliferation (A) and survival (B) of CCRF-CEM cells cultured in the presence of CAL-130 or vehicle control. *p < 0.01, **p < 0.001 for CAL-130 treated
(2.5 mM) versus DMSO.
(C and D) Effect of the PI3Kd-specific inhibitor IC87114 (10 mM) on proliferation (C) and survival (D) of CCRF-CEM cells in which p110g expression was knocked
down by shRNA transfection. **p < 0.001 for p110g shRNA treatedwith IC87114 versus nonsilencing vector treated with IC87114. Inset in (C) depicts western blot
analysis for p110 catalytic subunits.
(E–H) Proliferation and survival of CCRF-CEM cells cultured in the presence of dexamethasone alone (E and F) or in combination with 2.5 mMCAL-130 (G and H).
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See also Figure S3.
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Role of PI3Kg and PI3Kd in PTEN Null T-ALL(Foukas et al., 2010). To date, to our knowledge, no conclusive
evidence exists to implicate PI3Kb or any other class I PI3K in
the genesis of hematological malignancies such as T-ALL.
Our results demonstrate that in the absence of physiological
regulation, the activity of either PI3Kg or PI3Kd is sufficient for466 Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc.the malignant transformation of T cell progenitors in a living
animal. This is exemplified by the similar onset of disease and
percent survival of mice lacking either p110g or p110d, and the
rare incidence of tumor development in their combined absence.
Moreover, pharmacological blockade of both p110g and p110d
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antibodies. The PI3Kd-specific inhibitor IC87114 (IC) is shown for comparison.
(B) Representative immunoblots demonstrating activation of the proapoptotic pathway in CAL-130-treated CCRF-CEM cells.
(C) Representative bioluminescence images (upper panel) and quantification of tumor mass changes (lower panel) in mice with subcutaneous CCRF-CEM
xenografts that received vehicle control or CAL-130 for 4 days (n = 7).
(D) Kaplan-Meyer analysis of overall survival of mice treated with vehicle control or CAL-130 for 7 days in a systemic CCRF-CEM xenograft model (p < 0.01 for
CAL-130 treated versus vehicle control; n = 7 per group).
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Role of PI3Kg and PI3Kd in PTEN Null T-ALLdramatically impacted on tumor cell proliferation and survival as
demonstrated in CAL-130 treatment of diseased Lck/Ptenfl/fl
mice, IC87114 treatment of diseased Lck/PTENfl/fl;Pik3cg/
mice, as well as CAL-130 treatment of PTEN null human T-ALL
primary tumors or tumor cell lines; no such effects were
observed with siRNA knockdown of either p110a or p110b,
and selective blockade of PI3Kd with IC87114 was ineffective
in reducing the viability of primary human T-ALL samples. These
results would suggest that propagation of upstream signaling
pathways critical for the development and/or survival of PTEN
null T-ALL tumors relies on PI3Kg and PI3Kd and that the remain-
ing isoforms (i.e., a and b) cannot adequately compensate for
their inactivity. Clearly, the same PI3K isoforms can participate
in both tumorigenesis and tumor maintenance.
It has previously been established that PTEN loss is necessary
but not sufficient to cause the malignant transformation of T cell
progenitors (Liu et al., 2010; Guo et al., 2011). This typically
requires additional genetic events such as chromosomal translo-
cations involving the TCR a/d locus and c-myc oncogene (Ber-
nard et al., 1988; Finger et al., 1986), which are acquired during
the transition from CD4CD8 DN to CD4+CD8+ DP develop-ment stage. Despite the presence of these strong oncogenic
signals, the combined absence of PI3Kg and PI3Kd significantly
impaired leukemogenesis, suggesting that loss of these isoforms
can act as a tumorigenic bottleneck. Although it is possible
that the overall reduction in CD4+CD8+ DP thymocyte numbers
can partially account for the lower tumor incidence, we have
previously shown that the transition from DN to DP thymocyte
population in double-knockout mice is relatively normal (Swat
et al., 2006). That is to say, there is no major deficiency in the
number of early T cell progenitors that could undergo malignant
transformation in the absence of PTEN activity. Yet, not only is
tumorigenesis disrupted in TKO mice, but the abnormality
observed in T cell development persisted as well. This is in
contrast to the severe defect in thymocyte development associ-
ated with a genetic deletion of phosphoinositide-dependent
kinase 1 (PDK1) (Hinton et al., 2004), a direct downstream target
of class I PI3K, which can be overcome by the loss of PTEN
resulting in near-normal numbers of thymocytes and peripheral
T cells (Finlay et al., 2009). Similarly, PTEN deficiency can bypass
a defect in either IL-7R or pre-TCR signaling, which are critical for
the normal development and survival of T cells (Hagenbeek et al.,Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc. 467
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Figure 7. Susceptibility of Primary Human T-ALL Tumor Cells to Combined Inhibition of p110g and p110d
(A) Cell survival analyses of tumors cultured in the presence of increasing concentrations of CAL-130 for 72 hr. Percent viability indicates the proportion of live-
gated cells in the treated populations relative to its vehicle control counterpart. Data represent the mean ± SD of experiments performed in duplicate or triplicate.
*p < 0.01, **p < 0.001 for CAL-130 treated versus DMSO control. nd, not done; ns, not significant.
(B) Representative immunoblots of four primary human T-ALL samples to assess for expression of p110 catalytic domains and PTEN as well as phosphorylation
state of Akt.
(C) Effect of CAL-130 on Akt phosphorylation on the same four representative T-ALL samples after 6 hr of treatment. Densitometry was performed on bands from
immunoblots. The P-Akt signal was normalized to total Akt.
(D) Quantitative reverse-transcription PCR analysis of PIK3C (A/B/G/D) transcript levels in human thymocytes (n = 5) and primary human T-ALL tumors (n = 5).
Error bars represent ±SD. The difference in PIK3C expression levels between the thymocytes and tumor cells was not statistically significant (p > 0.05) using
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Role of PI3Kg and PI3Kd in PTEN Null T-ALL2004). In stark contrast to these studies is the inability of a PTEN-
deficient state to promote thymocyte proliferation and develop-
ment in TKO mice. Taken together, these observations further
suggest that developmental and genomic events responsible
for the generation as well as the malignant transformation of
T cells in the context of a PTEN-deficient state are critically
reliant on proliferation and survival signals provided by PI3Kg
and PI3Kd.
It is interesting to note that although PTEN appears to play
a key role in regulating the activities of class I PI3K, it is not the
only phosphatase in T cells. SHIP1 (SH2-containing inositol-50-
phosphatase) is also capable of hydrolyzing PIP3 and has
been shown to play an important role in the immunoregulatory
capacity and development of specific subsets of T cells (Tara-
senko et al., 2007; Collazo et al., 2009). Although deletion of
SHIP1 alone in T cell progenitors is not sufficient to induce leuke-468 Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc.mogenesis, low levels of this phosphatase in conjunction with
PTEN inactivation have been reported in human T-ALL tumors
suggesting that inactivation of both phosphatases contribute
to the hyperactivation of the PI3K/Akt signaling pathway (Lo
et al., 2009). Our discovery that both PI3Kg and PI3Kd are the
engines that help drive the oncogenic process in T cell progeni-
tors in the absence of appropriate regulation and can provide
sufficient growth and survival signals necessary for tumor cell
maintenance makes them attractive targets for therapy in such
clinical cases. Moreover, dual inhibition of PI3Kg and PI3Kd in
combination with conventional chemotherapies such as gluco-
corticoids may be of particular clinical utility in such individuals
because they are more likely to fail induction chemotherapy
and relapse (Gutierrez et al., 2009; Jotta et al., 2010).
It has been suggested that a complex signaling network
involving PI3K exists between leukemic and supporting cells in
Cancer Cell
Role of PI3Kg and PI3Kd in PTEN Null T-ALLthe tissue microenvironment that may contribute to disease
progression and drug resistance (Ayala et al., 2009; Konopleva
et al., 2009; Burger et al., 2009). This is exemplified by the recent
observations that the PI3Kd-specific inhibitor CAL-101 reduces
levels of circulating chemokines known to contribute to tissue
localization of chronic lymphocytic leukemic cells (Hoellenriegel
et al., 2011). Consequently, this results in a generalized lympho-
cytosis during treatment of patients with this hematological
malignancy. In contrast we have observed a dramatic and sus-
tained reduction in peripheral blood T-ALL cells within hours of
CAL-130 treatment of diseased Lck/Ptenfl/fl mice (data not
shown). That said, it is possible that paracrine and/or autocrine
signaling responsible for T-ALL survival in tissues may be
disrupted by simultaneously blocking the activities of PI3Kg
and PI3Kd. Further work will be required to establish the role
of these PI3K isoforms in supporting microenvironmental inter-
actions in T-ALL.
In the broader perspective our results indicate that in the
absence of PTEN-mediated regulation, distinct class I PI3K
can predominate in the development and survival of tumors in
a manner that is most likely to involve isoforms that normally
play a critical role in the function of that particular cell type.
Furthermore, we demonstrate that it is possible to target cancer
cells by exploiting their ‘‘addiction’’ to the activity of distinct PI3K
isoforms that are not themselves classical oncogenes. More
generally, by identifying PI3Kg and PI3Kd as key therapeutic
targets, it may be possible to limit toxicities that would be
associated with the administration of pan-PI3K or Akt inhibitors
including perturbations in insulin signaling and glucose metabo-
lism (Crouthamel et al., 2009).
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents and Antibodies
CCRF-CEM, CEM/C1, and MOLT-4 cells were obtained from ATCC and
grown in RPMI-1640 medium containing 10% FBS and antibiotics. Antibodies
to Akt (catalog #9272), phospho-Akt (S473, clone 193H12), phospho-mTOR
(S2448, catalog #2971S), mTOR (catalog #2972), phospho-GSK3a/b (S21/9,
catalog #9331S), GSK-3b (clone 27C10), phospho-p70S6K (Thr389, catalog
#9205S), p70S6K (catalog #9202), and b-actin (catalog #4967S) were
from Cell Signaling Technology. Antibodies to class I PI3K subunits were as
follows: p110a (catalog #4255) from Cell Signaling Technology; p110b (clone
Y384) from Millipore and mouse p110b from Santa Cruz Biotechnology
(catalog #sc-602); p110g (clone H1) from Jena Biosciences; and p110d (clone
H-219) from Santa Cruz Biotechnology. Antibodies to PTEN (clone 6H2.1)
were from Cascade Bioscience. For flow cytometry, antibodies were obtained
from BD Biosciences: CD3ε-Alexa 488 (clone 145-2C11), CD4-APC (clone
RM4-5), CD8-PerCP-Cy5.5 (clone 53-6.7), CD90.2-APC (Thy-1.2, clone
53-2.1), Ki67-FITC (clone B56), and Annexin V-APC. Antibodies to Bim, phos-
pho-Bad, Bad, and BclXL were from Cell Signaling Technology (proapoptotic
sampler kit #9942S).
The shRNA construct for p110g in the pLKO.1 vector was obtained from
Sigma-Aldrich (MISSION shRNA Plasmid DNA; clone ID: NM_002649.2-
4744s1c1; TRC number: TRCN0000196870). siRNA constructs for p110a
(ON-TARGET plus SMARTpool #L-003018-00) and p110b (ON-TARGET plus
SMARTpool # L-003019-00) were obtained from Dharmacon (Thermo
Scientific).
Primary Leukemia Samples
Cryopreserved samples were provided by collaborating institutions in the
United States (Department of Pediatrics, Columbia Presbyterian Hospital
and Departments of Medicine and Pathology, Vanderbilt University), The
Netherlands (Erasmus MC-Sophia Children’s Hospital), and Italy (Hemato-Oncology Laboratory, Department of Pediatrics, University of Padua). All
samples were collected with informed consent and under the supervision of
the Medical Ethics Committee of the Erasmus Medical Center, the Columbia
University Medical Center Institutional Review Board, the Vanderbilt University
Medical Center Institutional Review Board, and the Acute Lymphoblastic
Leukemia Strategic Scientific Committee.
Cell Counts, Cell Proliferation, and Cell Viability Assay
Cell counts for mice thymi were determined as previously described by Swat
et al. (2006). Cell proliferation of CCRF-CEM cells or shRNA-transfected
CCRF-CEM cells, in presence or absence of appropriate drug, was followed
by cell counting of samples in triplicate using a hemocytometer and trypan
blue. For apoptosis determinations of untransfected or shRNA-transfected
CCRF-CEMs, cells were stained with APC-conjugated Annexin-V (BD Biosci-
ences) in Annexin Binding Buffer (Miltyeni Biotec) and analyzed by flow
cytometry. For primary T-ALL samples, cell viability was assessed using the
BD Cell Viability kit (BD Biosciences) coupled with the use of fluorescent-
counting beads as previously described by Armstrong et al. (2009). For this,
cells were plated with MS5-DL1 stroma cells, and after 72 hr following drug
treatment, cells were harvested and stained with an APC-conjugated anti-
human CD45 followed by a staining with the aforementioned kit according to
the manufacturer’s instructions.
CAL130 IC50
CAL-130 is a derivative of IC87114, the synthesis of which has been previously
described by Sadhu et al. (2003). IC50 values for CAL-130 inhibition of PI3K
isoforms were determined in ex vivo PI3 kinase assays using recombinant
PI3K. A ten-point kinase inhibitory profile was determined with ATP at
a concentration consistent with the KM for each enzyme (Puri et al., 2004).
Calcium Flux Measurements in Thymocytes
Ca2+ flux measurements in single-cell suspensions of mouse thymocytes
were performed as previously described by Swat et al. (2006). Drug inhibition
of Ca2+ flux was measured after 30 min preincubation with CAL-130 at room
temperature of dye-loaded cells. Percent overall change inCa2+ flux is reported
as (Ca2+ fluxpeak  Ca2+ fluxbaseline/Ca2+fluxionomycin  Ca2+ fluxbaseline) 3 100.
Flow Cytometry for Cell Surface Staining and Apoptosis
For cell surface staining in mouse whole blood, following incubation with
appropriate antibodies, blood was processed using the BD Bioscience BD
FACS Lysing Solution according to the manufacturer’s instructions. For intra-
cellular staining of Ki67, immediately after RBC lysis with the BD FACS Lysing
solution, cells were permeabilized without washing with 0.025% Tween 20 in
lysing solution for an additional 15 min, washed, and then incubated with
Ki67 antibodies. For thymocytes, single-cell suspensions of thymocytes
were isolated and stained with the appropriate antibodies as previously
described by Swat et al. (2006).
Histological and Immunohistochemical Study of Tissue Samples
Formalin-fixed paraffin-embedded 5 mm tissue sections were stained with
hematoxylin and eosin for histopathological diagnosis. For immunohisto-
chemistry we performed anti-CD3 (rabbit polyclonal; Dako) staining on
tissue sections after antigen retrieval by microwave heating in citrate buffer
(pH 6.0). After epitope recovery, slides were incubated with antibody
(anti-CD3 1:50) overnight at room temperature before antigen detection
with diaminobenzidine (DAB) using a Ventana automated staining platform
(Ventana).
Western Blotting
Cell lysates (from cell lines or thymocytes) were prepared on ice in M-PER
Mammalian Protein Extraction reagent (Pierce) containing a cocktail of
protease and phosphatase inhibitors as previously described by Swat et al.
(2006). Equal amounts of total protein from lysates were subjected to
SDS-PAGE, transferred to PVDF membrane (Immobilon-P; Millipore),
and membranes were probed by overnight incubation with appropriate
primary antibodies. Bound antibodies were visualized with HRP-conjugated
secondary antibodies and ECL chemistry (SuperPico West; Pierce).Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc. 469
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CCRF-CEMs were transfected using the Amaxa Human T cell Nucleofecor
kit (Lonza) according to the manufacturer’s optimized protocol kit for
this cell line. For shRNA knockdown of p110g, CCRF-CEMs (2 3 106 cells)
were transfected with 2 mg of purified plasmid DNA, and clones were
selected by high dilution in puromycin used at a concentration predetermined
by a killing curve. Expression of p110g and p110d was determined by western
blotting.
For siRNA knockdown of p110a or p110b, CCRF-CEMs (2 3 106 cells)
were transfected with 300 nM of siRNA construct. After a brief recovery
period, cells were diluted to between 1 and 2 3 105/ml and grown for further
48 hr for cell counting, flow cytometry, and western blotting.
Mice and Animal Procedures
All mice were kept in a specific pathogen-free facility at Columbia University
Medical Center. All mice studies and breeding were carried out under the
approval of Institutional Animal Care and Use Committee of Columbia Univer-
sity. NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz mice for xenograft experiments and
Gt(ROSA)26Sortm1(Luc)Kael/J for bioimaging studies were obtained from The
Jackson Laboratory. Mice deficient for Pten in the T cell lineage were gener-
ated by crossing Lck-cre with floxed Pten (Hennet et al., 1995; Trotman
et al., 2003). P110g/ and p110d/ mice have been previously described
by Swat et al. (2006). These animals were intercrossed with Lck-cre/Ptenfl/fl
animals to generate mice homozygous mutant for either p110g or p110d and
Pten or homozygous mutant for p110g, 110d, and Pten.
For subcutaneous xenograft experiments, luminescent CCRF-CEM (CEM-
luc) cells were generated by lentiviral infection with FUW-luc and selection
with neomycin. Luciferase expression was verified with the Dual-Luciferase
Reporter Assay kit (Promega). We injected 2.5 3 106 CEM-luc cells
embedded in Matrigel (BD Biosciences) in the flank of NOD.Cg-Prkdcscid
Il2rgtm1Wjl/Sz mice. After 1 week, mice were treated by oral gavage with
vehicle (0.5% methyl cellulose, 0.1% Tween 80), or CAL-130 (10 mg kg1)
every 8 hr daily for 4 days, and then tumors were imaged as follows: mice
anesthetized by isoflurane inhalation were injected intraperitoneally with
D-luciferin (50 mg kg1; Xenogen). Photonic emission was imaged with the
In Vivo Imaging System (IVIS; Xenogen). Tumor bioluminescence was
quantified by integrating the photonic flux (photons per second) through
a region encircling each tumor using the Living Image software package
(Xenogen). Administration of D-luciferin and detection of tumor biolumines-
cence in Lck/Ptenfl/fl/Gt(ROSA)26Sortm1(Luc)Kael/J mice were performed in
a similar manner.
For intravenous xenograft transplantation, 5 3 106 CCRF-CEM cells were
injected intravenously in 14 NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz mice. After
3 days, mice were segregated into two treatment groups that received either
CAL-130 or vehicle by oral gavage as described above for 7 days. Mice in
both groups were then followed until moribund (and euthanized).
Plasma Levels of CAL130, Glucose, and Insulin
For CAL-130 level determinations, animals received a single oral dose (10 or
20 mg kg1) of inhibitor. Plasma was collected at 0, 2, 4, 8, and 12 hr and
subjected to high-performance liquid chromatography-MS/MS (sensitivity
1 ng/ml). The concentration of CAL-130 in plasma was determined using
a standard curve (analyte peak area versus concentration) generated with
calibration standard pools. Values represent the mean (±SD) for four animals
per group.
Plasma glucose and insulin levels were determined following a single oral
dose of CAL-130 (10 mg kg1). Blood was collected into K2EDTA tubes by
cardiac puncture at baseline and 0, 2, 4, and 8 hr post-dose, and plasma
samples were frozen at 80C until analysis. The insulin and glucose levels
were determined by using an Ultra Sensitive Mouse Insulin ELISA Kit (Crystall
Chem) or WaveSense Presto Blood Glucose Monitoring System (Agamatrix,
Boston), respectively.
Statistical Analyses
Statistical analyses were performed using Student’s t test (GraphPad
Prism software). Kaplan-Meier survival curves were analyzed using a log
rank test (GraphPad Prism software). Values were considered significant at
p < 0.05.470 Cancer Cell 21, 459–472, April 17, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
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